CytomX Therapeutics (CTMX)
(Real Time Quote from BATS)
$1.15 USD
0.00 (0.00%)
Updated Sep 24, 2024 10:12 AM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 81 - 100 ( 158 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2020 Takeaways: CX-2029 and CX-2009 Show Positive Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR II 2020 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Abstracts Raise More Questions Than Answers; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on ASCO Presentations; 1Q20 Financials Reported; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; ASCO Data Updates Ahead for Key Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-2029 Data Trigger Milestone Payment; Pipeline Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Astellas Pays up for Bispecifics; Upgrading to OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CytomX Inks Astellas Agreement on Probody Bispecifics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financial Results Reported; Multiple 2020 Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Platform Progresses with Data-Rich Year Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BMS-986249 Plus Opdivo to Be Tested in Melanoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-2009 Targeting HR+, HER2 Metastatic Breast Cancer First; Upcoming 2020 Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-2009 Advanced into HR+/HER2- Breast Cancer; Pipeline Update
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Downgrading to NEUTRAL as Development Paths Remain Unclear
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Financials Reported; Reiterate Buy and Reducing PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Multiple Strategic Updates Expected in 2H19
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R